Advertisement
Advertisement
U.S. Markets open in 4 hrs 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
163.36-1.25 (-0.76%)
At close: 04:00PM EST
163.58 +0.22 (+0.13%)
Pre-Market: 04:37AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close164.61
Open164.55
Bid0.00 x 900
Ask163.60 x 800
Day's Range163.10 - 164.85
52 Week Range155.72 - 186.69
Volume7,005,314
Avg. Volume7,080,273
Market Cap427.101B
Beta (5Y Monthly)0.56
PE Ratio (TTM)28.86
EPS (TTM)5.66
Earnings DateApr 17, 2023 - Apr 21, 2023
Forward Dividend & Yield4.52 (2.62%)
Ex-Dividend DateNov 21, 2022
1y Target Est183.80
  • Financial Times

    The jig is up for the Texas two-step

    Today is Tuesday, February 7th, and this is your FT News Briefing. Johnson & Johnson can no longer sidestep certain liability lawsuits. Google is playing catch-up with its artificial intelligence technology.

  • Benzinga

    Johnson & Johnson's Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder

    Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for pregnant adults at high risk for severe hemolytic disease of the fetus and newborn. In 2020, Johnson & Johnson shelled out $6.5 billion to acquire Momenta Pharmaceuticals Inc, gaining access to its lead product, nipocalimab. HDFN is a rare condition that can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and

  • Zacks

    Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL

    Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.

Advertisement
Advertisement